| P2093 | author name string | Omar Abdel-Rahman | |
| P2860 | cites work | Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models | Q38887681 |
| | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer | Q38945477 |
| | MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib | Q39252829 |
| | KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach | Q39720116 |
| | A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens | Q42673662 |
| | Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines | Q43413826 |
| | Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airway-tumour-stroma lung cancer model | Q50282908 |
| | RAS oncogenes: the first 30 years. | Q55036584 |
| | Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies | Q21092363 |
| | COSMIC 2005 | Q24652464 |
| | A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response | Q27851728 |
| | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 |
| | RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells | Q27853064 |
| | Targeting RAS signalling pathways in cancer therapy | Q28201363 |
| | Mammalian MAP kinase signalling cascades | Q28204140 |
| | KRAS mutations in non-small cell lung cancer | Q28240568 |
| | RAF protein-serine/threonine kinases: Structure and regulation | Q28289378 |
| | Characteristics of lung cancers harboring NRAS mutations | Q28706226 |
| | Executive Summary | Q29036133 |
| | The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study | Q30539397 |
| | Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models | Q33820374 |
| | The molecular perspective: the ras oncogene. | Q33867083 |
| | Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines | Q34129528 |
| | Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells | Q34273541 |
| | Clinical experience of MEK inhibitors in cancer therapy | Q34595700 |
| | Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study | Q34652628 |
| | Antitumor activity in RAS-driven tumors by blocking AKT and MEK. | Q35103514 |
| | Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors | Q35212644 |
| | Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis | Q35836350 |
| | Inhibition of Ras for cancer treatment: the search continues | Q35944601 |
| | Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery | Q36162904 |
| | Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer | Q36834504 |
| | A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. | Q36865033 |
| | Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor | Q36929804 |
| | Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? | Q37110396 |
| | Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 |
| | Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. | Q38586046 |
| | Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis | Q38626515 |
| | Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. | Q38631710 |
| P433 | issue | 3 | |
| P304 | page(s) | 265-274 | |
| P577 | publication date | 2016-02-18 | |
| P1433 | published in | Therapeutic advances in respiratory disease | Q26842252 |
| P1476 | title | Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations | |
| P478 | volume | 10 | |